HD-OPM Archive
Topics › Hormones, women's & men's health

Israeli HRT study's 749% higher cancer risk at ages 50-65 is implausible, says oncologist

Louis Nervegna · Mar 19, 2026 · ♥ 13 reactions · 7 comments · original Facebook post
Hormones, women's & men's healthHow to read research
AI summary & key facts

Louis shares Dr. Brian Lawenda's critique of an observational Israeli study of over 83,000 women. Reported risk increases were larger in women starting HRT at 50-65 than after 65, which contradicts physiology and prior evidence, so he calls it a red flag and warns against overriding better evidence.

#hrtHD

Research cited

A lot of women are going to see headlines about this new hormone therapy study and come away frightened.

They shouldn’t.

This is a good example of why one study, especially an observational one, should never be allowed to override decades of better evidence.

The new Israeli study looked at more than 83,000 women and concluded that starting hormone therapy after age 65 was associated with higher risks of cancer and vascular events. That part is not especially shocking. It is broadly consistent with what we already believed about late initiation of hormone therapy. 

But that is not the part that caught my attention.

What stood out was how extreme the reported risks were in women who started hormone therapy between ages 50 and 65. In that group, the study reported a 749% higher cancer risk, a 1,569% higher stroke risk, and an 817% higher risk of ischemic heart disease or heart attack. For women who started after age 65, the reported increases were actually much smaller: about 122% higher cancer risk, 170% higher stroke risk, and roughly 139% higher risk of ischemic heart disease or heart attack. 

Think about that for a second.

The study is basically implying that starting hormone therapy at ages 50 to 65 was far more dangerous than starting it after 65.

That does not make physiologic sense. It does not fit clinical experience. And it does not fit the larger body of evidence we already have. 🙄

That is a giant red flag 🚩

This was not a randomized trial. It was a retrospective observational study. Women were not randomly assigned to hormones or no hormones. Doctors prescribed treatment based on symptoms, baseline health, prior hysterectomy status, cardiovascular risk, and many other factors that are hard to fully account for in a database. The authors also acknowledged missing historical information before 2000, which makes confounding even harder to sort out. 

That is how you can end up with numbers that look statistically polished but clinically implausible.

In fact, the Menopause Society’s summary of the study makes the problem pretty obvious. In crude analyses, women who started hormone therapy between 50 and 65 actually had lower rates of ischemic heart disease and MI before adjustment. Then, after adjustment, that apparent benefit flipped into massive harm. When a model reverses the story that dramatically and spits out huge risk estimates, you have to question whether the model is correcting for confounding or creating distortion. 

And this is exactly why one large study should not bulldoze decades of better evidence.

The broader literature has been much more consistent. When hormone therapy is started in women younger than 60, or within 10 years of menopause, the benefit-risk profile is generally the most favorable. Multiple reviews and scientific statements have supported the idea that earlier initiation is associated with lower coronary heart disease risk and lower all-cause mortality, while later initiation looks less favorable. 

The breast cancer story is also far more nuanced than most headlines suggest.

In the long-term follow-up of the Women’s Health Initiative, women with prior hysterectomy who took estrogen alone had lower breast cancer incidence and LOWER breast cancer mortality than women assigned to placebo. There were 238 breast cancers in the estrogen-alone group versus 296 in the placebo group, and 30 breast cancer deaths versus 46. That translated to a 22% lower breast cancer incidence and a 40% lower breast cancer mortality with estrogen alone. 

That is not a trivial detail. That is one of the most important and most misunderstood findings in this entire field.

By contrast, combined estrogen plus progestin is different. In the same long-term WHI follow-up, combined therapy was associated with higher breast cancer incidence, 584 cases versus 447 with placebo, or about a 28% increase. Breast cancer mortality, however, was not significantly increased. 

So the type of hormone therapy matters. A lot.

And age at initiation matters. A lot.

The bottom line is that this new Israeli study does not overturn the existing evidence base. If anything, it reinforces the point that starting hormone therapy later in life is riskier. But the dramatic findings in the 50 to 65 age group should be viewed with real skepticism, because they clash with biology, clinical experience, and much stronger prior evidence. 

📌 If you are under 60, or within about 10 years of menopause, and you have bothersome symptoms, hormone therapy remains a very reasonable option for many women after an individualized discussion of risks and benefits. If you have had a hysterectomy, estrogen-alone therapy may actually LOWER your breast cancer risk. If you are older, especially beyond 65, the decision becomes more cautious and more individualized. 

This is the bigger lesson.

Large studies are not automatically good studies.

If a result does not make clinical sense, it deserves scrutiny, not blind acceptance.

Good medicine means looking at the totality of evidence, understanding who the patient is in front of you, and not letting one flawed study drive the entire conversation.

Study:

Paper · Menopause · 2026Health outcomes of hormone therapy initiated or continued after age 65Objective: Menopausal hormone therapy (HT) is effective for alleviating vasomotor symptoms but remains controversial regarding long-term safety, particularly in women over 65. Despite guidelines recommending initiation before age 60, a notable proportion of older women continue or begin HT later in life. The health outcomes of HT in women aged 65 and older, especially those initiating therapy after 65, compared with…journals.lww.comNo photo description available.
#cancer#hormones#breastcancer#estrogen#heartdisease#mortality#menopause#heartattack
← newer: Elaine LaLanne turns 100, a plant-heavy, active lifestyle exolder: Aging muscle has elevated basal mTOR that blocks autophagy, →